Researchers, cancer patients, and philanthropists have come together to launch Count Me In, a new nonprofit organization and model of patient-partnered research. Count Me In allows cancer patients anywhere in the United States or Canada to easily share their medical information, personal experience, and tumor samples for genetic analysis, propelling progress against cancer. Patient information is rapidly processed, de-identified and made available to all researchers worldwide.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
